Company: FTII
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001641172-25-025250
Chunk: 97

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 2
Chunk 97
---

for its fully meaning and legal effect. A copy of the Amended Merger Agreement is filed with this Current Report as Exhibit 2.1 and is
incorporated herein by reference, and the foregoing description of the Merger Agreement is qualified in its entirety by reference thereto.

Pursuant
to the Amended Merger Agreement, Longevity shall, prior to the closing of the Reorganization Merger, consummate the Target Acquisitions
upon the terms and subject to conditions set forth therein and pursuant to the Target Acquisition Agreements. The Target Acquisitions
are the acquisitions by Longevity of each of Cerevast Medical, Inc. and Aegeria Soft Tissue, LLC (“Aegeria”) pursuant to
each of the Cerevast Acquisition Agreement and the Aegeria Acquisition Agreement, each in accordance with the respective terms thereof.

On
August 12, 2025, the Company consented (the “Approval of Waiver”) to Longevity entering into a waiver agreement with Aegeria
(the “Waiver Agreement”) to remove the restriction contained in the Aegeria Acquisition Agreement that prohibited Aegeria
from soliciting, negotiating, entering into, or otherwise facilitating an acquisition proposal or alternative transaction.

The
foregoing description of the Approval of Waiver and the Waiver Agreement does not purport to be complete and is qualified in its entirety
by the terms and conditions of the Approval of Waiver and the Waiver Agreement and any related agreements. A copy of the Approval of
Waiver and the Waiver Agreement are filed with this Current Report as Exhibits 10.1 and 10.2, respectively and are incorporated herein
by reference.

August
14, 2025 Stockholder Meeting.

As
approved by the Company’s stockholders at the special meeting of stockholders held on August 14, 2025, the Company filed a
Fourth Amendment (the “Fourth Amendment”) to its Amended and Restated Certificate of Incorporation (the “Charter”)
with the Delaware Secretary of State on August 15, 2025 to modify the terms and extend the date by which the Company has to consummate
an initial business combination for twelve one-month extensions from August 18, 2025 to August 18, 2026, provided that the Company deposits
the lesser of $25,000 and $0.033 for each outstanding share of common stock sold in the Company’s initial public offering into